Insider Buying: Phillip Md Et Al Frost Purchases 65,000 Shares of Opko Health Stock (OPK)
Opko Health (NYSE:OPK) CEO Phillip Md Et Al Frost acquired 65,000 shares of Opko Health stock on the open market in a transaction that occurred on Wednesday, June 25th. The shares were purchased at an average price of $8.65 per share, for a total transaction of $562,250.00. Following the completion of the transaction, the chief executive officer now directly owns 1,987,500 shares in the company, valued at approximately $17,191,875. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Opko Health (NYSE:OPK) traded up 1.02% during mid-day trading on Thursday, hitting $8.799. The stock had a trading volume of 388,220 shares. Opko Health has a 52-week low of $6.99 and a 52-week high of $12.95. The stock has a 50-day moving average of $8.76 and a 200-day moving average of $8.80. The company’s market cap is $3.641 billion.
Opko Health (NYSE:OPK) last posted its quarterly earnings results on Friday, May 9th. The company reported ($0.11) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.10) by $0.01. The company had revenue of $22.30 million for the quarter, compared to the consensus estimate of $22.77 million. Analysts expect that Opko Health will post $-0.38 EPS for the current fiscal year.
A number of analysts have recently weighed in on OPK shares. Analysts at Jefferies Group reiterated a “buy” rating on shares of Opko Health in a research note on Wednesday. They now have a $11.00 price target on the stock, down previously from $11.50. Separately, analysts at TheStreet upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Friday, May 30th. Finally, analysts at TheStreet downgraded shares of Opko Health from a “hold” rating to a “sell” rating in a research note on Tuesday, May 13th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $12.13.
OPKO Health, Inc (NYSE:OPK) is a multi-national biopharmaceutical and diagnostics company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.